Osteoporosis News: Merck Abandons Osteoporosis Drug

March 1, 2017

 

 

Yes, the Pharmaceutical distributer Merck & Co has discontinued the development of the osteoporosis drug Odanacatib. They also will NOT seek regulatory approval for the treatment.

 

Why?

 

A recent research study confirmed that using this drug greatly increases the risk of stroke. The data from the analysis was presented at the American Society for Bone Mineral Research.

 

Merck had planned and hoped to gain approval for Odanacatib in the U.S. and Japan. Researchers determined that while the drug showed the ability to reduce the risk of osteoporotic fractures, the INCREASED RISK OF STROKE outweighed any benefits.   

 

Merck had even tried to regain approval for the drug, even after the major risk factors emerged! Wow, how about that? The approval did not go through, and the company finally decided to discontinue the development of Odanacatib.

 

 

For a natural approach to osteopenia and/or osteoporosis watch Barbara Hoffman of Better Health Naturally’s videos here:

 

Email Barbara for the osteoporosis hand-out: Barbara@askbarbarahoffman.com 

 

As we all know, harsh pharmaceutical drugs can have serious side effects.

 

Let’s shop in God’s Pharmacy where we will not be harmed!

Share on Facebook
Share on Twitter
Please reload

Recent Posts

June 4, 2020

Please reload

© 2023 by Glorify. Proudly created with Wix.com